AVDL Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for sleep disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. EDT on Friday, March 15, 2019, to provide a corporate update and discuss details of the Company's financial results for the quarter and year ended December 31, 2018.

To access the conference call, investors are invited to dial (844) 388-0559 (U.S. and Canada) or (216) 562-0393 (international). The conference ID number is 7781559. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.

About Avadel Pharmaceuticals plc:

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a branded specialty pharmaceutical company.  Our primarily focus is on the development and potential FDA approval for FT218 which is in a Phase III clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy.  In addition, we market three sterile injectable drugs used in the hospital setting which were developed under our “unapproved marketed drug” (UMD) program.  The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, please visit www.avadel.com.

Cautionary Disclosure Regarding Forward-Looking Statements 

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results and financial condition and the market price of our American Depositary Shares (ADSs).  Factors that could cause actual results to differ materially from management’s current expectations include risks and uncertainties relating to our efforts to complete the development and attain regulatory approval of FT 218, our sodium oxybate product candidate for the treatment of narcolepsy, risks relating to our ability to achieve the anticipated results of our restructuring plan announced on February 6, 2019 and the other risks described in our filings with the Securities and Exchange Commission.  We do not undertake to publicly update or revise any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contacts:	Michael F. Kanan
	Chief Financial Officer
	Phone: (636) 449-1844
	Email: mkanan@avadel.com
	Alex Gray
	Burns McClellan
	Phone: (212) 213-0006
	Email: agray@burnsmc.com